8-KMaterial AgreementsOther EventsExhibits & Filings

AMGEN INC 8-K Report, Material Agreement (Aug 19, 2016)

Filed August 19, 2016For Securities:AMGN

Summary

Amgen Inc. (AMGN) filed a Form 8-K on August 19, 2016, to report a material definitive agreement concerning the issuance and sale of senior notes. The company successfully issued and sold a total of $4.75 billion in senior notes across four tranches: $750 million in 1.850% notes due 2021, $750 million in 2.250% notes due 2023, $1.25 billion in 2.600% notes due 2026, and $1 billion in 4.400% notes due 2045. The net proceeds from this offering amounted to approximately $3.80 billion after accounting for underwriters' discounts and offering expenses. This significant debt financing activity indicates Amgen's strategic approach to managing its capital structure and potentially funding future growth initiatives, research and development, or other corporate needs. The issuance of notes with varying maturities and coupon rates suggests a strategy to diversify its debt obligations and optimize borrowing costs. Investors should note the company's commitment to its debt obligations as detailed in the filing, including covenants and provisions for potential change in control events.

Key Highlights

  • 1Amgen Inc. issued and sold a total of $4.75 billion in Senior Notes on August 19, 2016.
  • 2The issuance comprises four tranches: 1.850% notes due 2021 ($750M), 2.250% notes due 2023 ($750M), 2.600% notes due 2026 ($1.25B), and 4.400% notes due 2045 ($1B).
  • 3Net proceeds from the offering were approximately $3.80 billion after deducting fees and expenses.
  • 4The 2045 Notes represent a further issuance and are fungible with the notes initially issued on May 1, 2015.
  • 5The notes rank equally with existing and future senior unsecured indebtedness and are senior to subordinated indebtedness.
  • 6The filing also includes the computation of Amgen's ratio of earnings to fixed charges for relevant periods.

Frequently Asked Questions

The primary purpose of this Form 8-K filing was to report Amgen's entry into a material definitive agreement regarding the issuance and sale of $4.75 billion in senior notes.

The filing does not explicitly state the intended use of the proceeds. However, significant debt issuances like this are typically undertaken to fund general corporate purposes, research and development, acquisitions, capital expenditures, or to refinance existing debt.

The new notes rank equally in right of payment with Amgen's other existing and future senior unsecured indebtedness. They are senior to any subordinated indebtedness and effectively subordinated to the obligations of Amgen's subsidiaries.

Yes, in the event of a 'change in control triggering event' as defined in the respective officer's certificates, holders of the notes may require Amgen to purchase their notes at 101% of the principal amount, plus accrued interest.